MYCN and neuroblastoma: Consistent with the in vivo models and patient datasets, a significant increase in CD68 positive macrophages was identified in ATRX mutant neuroblastomas compared with MYCN-amplified or non MYCN-amplified disease (Fig. 6C–D).